Business, energy, technology, markets and global industry news from Business News Today

Sumitomo Pharma

PharmaDeviceNews Sumitomo Pharma
Sumitomo Pharma’s investigational menin inhibitor enzomenib gains FDA orphan drug designation as development advances for acute lymphoblastic leukemia. Representative image.
Pharma & Biotech

Sumitomo Pharma’s enzomenib receives FDA orphan drug designation for acute lymphoblastic leukemia

FDA orphan drug status expands enzomenib’s ALL pathway as Sumitomo Pharma advances pivotal development in biomarker-defined acute leukemia.

Read More
Representative image of a urologist discussing overactive bladder and benign prostatic hyperplasia treatment data with an older male patient, reflecting Sumitomo Pharma America’s AUA 2026 vibegron findings in men aged 75 and older.
Pharma & Biotech

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.

Read More